UCB ADR Aktie

 

Although the revenue and EPS for United Community Banks (UCB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

United Community Banks (UCB) delivered earnings and revenue surprises of +6.45% and -0.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

United Community Banks (UCB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

UCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....

Does United Community Banks (UCB) have what it takes to be a top stock pick for momentum investors? Let's find out....

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does United Community Banks (UCB) have what it takes? Let's find out....

Genomenon's Curation and Distribution of Variant Data to Global Clinical Communities Reduces Barriers to Genetic Diagnosis ANN ARBOR, Mich., July 9, 2025 /PRNewswire/ -- Genomenon, a leader in genomic intelligence, today announced a strategic partnership with UCB to accelerate awareness,......

Inspired by feedback from the hidradenitis suppurativa (HS) community, the campaign aims to raise awareness of BIMZELX and features a broad range of educational materials encouraging patients to discuss treatment options with their healthcare providers ATLANTA, July 8, 2025 /PRNewswire/......

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

GREENVILLE, S.C., June 27, 2025 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NYSE: UCB) announces it will release its second quarter 2025 financial results on Wednesday, July 23, 2025, before the stock market opens. The company also will hold a conference call at 9:00 a.m. EST on Wednesday, July 23, 2025, to discuss its financial results, business highlights, and outlook....

Phase 3 study met primary and most key secondary clinical endpoints This marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase 3 results Results underscore the impact of UCB's continued investment in scientific innovation to......

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does United Community Banks (UCB) have what it takes? Let's find out....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

UCB will contribute three presentations, including data on the disease course of thymidine kinase 2 deficiency (TK2d) in untreated patients and insights into caregiver impact These data emphasize UCB's commitment to advancing treatment outcomes and patient experiences in TK2d and......

ATLANTA, June 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB Myasthenia Gravis Scholarship™ exemplifies UCB's dedication to supporting the rare disease......

Committed to serve U.S. patients and deliver economic impact of approximately $5 billion, including creation of 300 U.S. direct high skilled jobs and more than 500 construction jobs Scaling up U.S. based Contract Manufacturing Organization (CMO) partnerships to support the growth of UCB's......

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care. read more...

WESTON (dpa-AFX) - UCB (UCB) and Biogen Inc. (BIIB) presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug c......

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology's annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizu...